Abstracts

Faldaprevir Plus Pegylated Interferon Alfa-2a/Ribavirin in HIV/HCV Co‑infection: STARTVerso4

Background: Faldaprevir (FDV) is a potent, once-daily HCV NS3/4A protease inhibitor being developed for the treatment of chronic HCV infection in monoinfected patients and patients co-infected with HIV. The objective of STARTVerso4 is to assess efficacy and safety of FDV + pegylated interferon alfa-2a/ ribavirin (PR), and evaluate response-guided treatment duration in HIV patients co-infected…

Simeprevir (TMC435) Plus PegIFN/ribavirin in HCV Genotype-1/HIV-1 Coinfection (Study C212)

Background: Simeprevir (TMC435, SMV) is a potent, oral, once-daily (QD), investigational HCV NS3/4A protease inhibitor with activity against HCV genotypes 1, 2, 4, 5, and 6. This ongoing Phase III, open-label trial is investigating efficacy and safety of SMV plus peginterferon/ribavirin (PR) in treatment-naive or -experienced patients (pts) co-infected with HCV genotype 1 and HIV-1.…

All-Oral Combination of Daclatasvir Asunaprevir and BMS-791325 for HCV*Genotype 1 Infection

Background: The all-oral triple combination of daclatasvir (DCV; NS5A inhibitor), asunaprevir (ASV; NS3 inhibitor), and BMS-791325 (‘325; nonnucleoside NS5B inhibitor) achieved sustained virologic response (SVR) rates >90% in pilot cohorts of non-cirrhotic patients with chronic HCV genotype (GT)1 infection. The present study expansion (AI443-014) evaluates this regimen in larger cohorts that include cirrhotic patients, with…

Sofosbuvir Plus Ribavirin for HCV Genotype 1-3 Infection in HIV-Coinfected Patients (PHOTON-1)

Background: Interferon-free treatments for HCV that can be safely co-administered with antiretroviral therapy (ART) are needed for HIV/HCV co-infected patients. We evaluated the safety and efficacy of sofosbuvir (SOF), a pan-genotypic HCV NS5B inhibitor, with ribavirin (RBV) in HCV genotype (GT) 1-3 patients co-infected with HIV. Methodology: HCV patients with stable HIV disease received SOF…

Combination Oral Hepatitis C Antiviral Therapy for 6 or 12 Weeks: Final Results of the SYNERGY Trial

Background: Combining multiple directly acting antiviral agents (DAA) is a plausible approach to reduce the duration of therapy require to cure HCV infection. In this study treatment regimens targeting multiple stages of HCV replication were evaluated for safety and efficacy in a historically difficult to treat population. Methodology: Sixty HCV mono-infected, treatment naive, GT-1, patients…

Daclatasvir in Combination With Simeprevir ± Ribavirin for Hepatitis C Virus Genotype 1 Infection

Background: All-oral combinations of direct-acting antivirals offer potential for effective and well tolerated HCV therapies. We assessed the efficacy and safety of daclatasvir (DCV; NS5A inhibitor) combined with simeprevir (SMV; NS3/4A protease inhibitor), with or without ribavirin (RBV), in patients with HCV genotype (GT) 1 infection. Methodology: In this open-label study (AI444-062), HCV GT1b treatment-naive…

PEARL III: SVR ≥99% After 12 Wks of ABT-450/r/267 + ABT-333 ± RBV in Treatment Naïve HCV GT1b Infection

Background: ABT-450 is an HCV protease inhibitor (dosed with ritonavir 100mg, ABT-450/r) identified by AbbVie and Enanta. ABT-267 is an NS5A inhibitor, and ABT-333 is a nonnucleoside polymerase inhibitor. Genotype 1b (GT1b) infection is more common globally than GT1a; thus there is a large unmet need for safe, efficacious and simple therapy. In a prior…

HIV-1 Resistance After Randomized Virologic Switch at 1000 or 30 000 c/ml in Children

Background: There are no comparisons of resistance after randomized virologic switch criteria. Methodology: PENPACT 1 was an international open label 2 by 2 factorial trial randomizing HIV infected children to start antiretrovirals with a protease inhibitor (PI) vs non nucleoside reverse transcriptase inhibitor (NNRTI) based regimen, and switch at RNA threshold of 1000 vs 30000…

Prevalence and Predictors of HIV Drug Resistance Among US Children and Youth With Perinatal HIV

Background: With extensive antiretroviral (ARV) exposure and the challenge of maintaining adherence, children and youth with perinatal HIV are at high risk for acquired drug resistance. Methodology: The Adolescent Master Protocol of the Pediatric HIV/AIDS Cohort Study is a prospective study being conducted at 14 U.S. sites. From 2007 to 2009, we enrolled 451 subjects…